Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Eli Lilly And Co (LLY) Price & Performance

iShares JPMorgan USD Emerging Markets Bond ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

iShares JPMorgan USD Emerging Markets Bond ETF vs Eli Lilly And Co — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Eli Lilly And Co trades at $1,216.25 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals.

EMBLLY
Sector
Fixed IncomeHealth
52-Week High
$97.74$1.24K
52-Week Low
$92.95$635.22
Market Cap
$1.10T
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares JPMorgan USD Emerging Markets Bond ETF

EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.

Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares JPMorgan USD Emerging Markets Bond ETF

EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.

Read more on EMB

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY